BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgrad Med 2021;133:489-507. [PMID: 33245005 DOI: 10.1080/00325481.2020.1855921] [Cited by in Crossref: 10] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Abraham S, Manohar SA, Patel R, Saji AM, Dani SS, Ganatra S. Strategies for Cardio-Oncology Care During the COVID-19 Pandemic. Curr Treat Options Cardio Med. [DOI: 10.1007/s11936-022-00965-2] [Reference Citation Analysis]
2 Jiang Y, Zhao T, Zhou X, Xiang Y, Gutierrez‐castrellon P, Ma X. Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions. MedComm 2022;3. [DOI: 10.1002/mco2.154] [Reference Citation Analysis]
3 Tahsini Tekantapeh S, Ghojazadeh M, Ghamari AA, Mohammadi A, Soleimanpour H. Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients with moderate to severe COVID-19 pneumonia: a systematic review and meta-analysis. Expert Rev Respir Med 2022. [PMID: 35981253 DOI: 10.1080/17476348.2022.2114899] [Reference Citation Analysis]
4 Chen M, Ma Y, Chang W. SARS-CoV-2 and the Nucleus. Int J Biol Sci 2022;18:4731-43. [PMID: 35874947 DOI: 10.7150/ijbs.72482] [Reference Citation Analysis]
5 Ni Y, Low JT, Silke J, O'Reilly LA. Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. Front Immunol 2022;13:835997. [PMID: 35844493 DOI: 10.3389/fimmu.2022.835997] [Reference Citation Analysis]
6 Malekinejad Z, Baghbanzadeh A, Nakhlband A, Baradaran B, Jafari S, Bagheri Y, Raei F, Montazersaheb S, Farahzadi R. Recent clinical findings on the role of kinase inhibitors in COVID-19 management. Life Sci 2022;306:120809. [PMID: 35841979 DOI: 10.1016/j.lfs.2022.120809] [Reference Citation Analysis]
7 Andaluz-Ojeda D, Vidal-Cortes P, Aparisi Sanz Á, Suberviola B, Del Río Carbajo L, Nogales Martín L, Prol Silva E, Nieto del Olmo J, Barberán J, Cusacovich I. Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. World J Crit Care Med 2022; 11(4): 269-297 [DOI: 10.5492/wjccm.v11.i4.269] [Reference Citation Analysis]
8 Huang J, Zhou C, Deng J, Zhou J. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Biochem Pharmacol 2022;:115162. [PMID: 35787993 DOI: 10.1016/j.bcp.2022.115162] [Reference Citation Analysis]
9 Zhuang Z, Zhong X, Chen Q, Chen H, Liu Z. Bioinformatics and System Biology Approach to Reveal the Interaction Network and the Therapeutic Implications for Non-Small Cell Lung Cancer Patients With COVID-19. Front Pharmacol 2022;13:857730. [PMID: 35721149 DOI: 10.3389/fphar.2022.857730] [Reference Citation Analysis]
10 Chandrasekaran B, Saravanan M. Editorial: Pharmacological and Biochemical Perspectives of Kinase Inhibitors in Cancer and COVID-19 Therapeutics, Volume I. Front Pharmacol 2022;13:916324. [DOI: 10.3389/fphar.2022.916324] [Reference Citation Analysis]
11 Zheng J, Miao J, Guo R, Guo J, Fan Z, Kong X, Gao R, Yang L. Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2. Front Cell Infect Microbiol 2022;12:931061. [DOI: 10.3389/fcimb.2022.931061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bahmani M, Chegini R, Ghanbari E, Sheykhsaran E, Shiri Aghbash P, Leylabadlo HE, Moradian E, Kazemzadeh Houjaghan AM, Bannazadeh Baghi H. Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade. World J Virol 2022; 11(3): 113-128 [DOI: 10.5501/wjv.v11.i3.113] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Roig-Marín N, Roig-Rico P. Cardiac auscultation predicts mortality in elderly patients admitted for COVID-19. Hosp Pract (1995) 2022. [PMID: 35468303 DOI: 10.1080/21548331.2022.2069772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Niedźwiedzka-Rystwej P, Majchrzak A, Kurkowska S, Małkowska P, Sierawska O, Hrynkiewicz R, Parczewski M. Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm. Int J Mol Sci 2022;23:4545. [PMID: 35562935 DOI: 10.3390/ijms23094545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gavriilidis E, Antoniadou C, Chrysanthopoulou A, Ntinopoulou M, Smyrlis A, Fotiadou I, Zioga N, Kogias D, Natsi AM, Pelekoudas C, Satiridou E, Bakola SA, Papagoras C, Mitroulis I, Peichamperis P, Mikroulis D, Papadopoulos V, Skendros P, Ritis K. Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure. Clin Immunol 2022;:109016. [PMID: 35447311 DOI: 10.1016/j.clim.2022.109016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 López-Cortés A, Guerrero S, Ortiz-Prado E, Yumiceba V, Vera-Guapi A, León Cáceres Á, Simbaña-Rivera K, Gómez-Jaramillo AM, Echeverría-Garcés G, García-Cárdenas JM, Guevara-Ramírez P, Cabrera-Andrade A, Puig San Andrés L, Cevallos-Robalino D, Bautista J, Armendáriz-Castillo I, Pérez-Villa A, Abad-Sojos A, Ramos-Medina MJ, León-Sosa A, Abarca E, Pérez-Meza ÁA, Nieto-Jaramillo K, Jácome AV, Morillo A, Arias-Erazo F, Fuenmayor-González L, Quiñones LA, Kyriakidis NC. Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials. Front Pharmacol 2022;13:833174. [PMID: 35422702 DOI: 10.3389/fphar.2022.833174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wei J, Shang R, Wang J, Zhu S, Yin J, Chen Y, Zhao Y, Chen G. ACE2 overexpressing mesenchymal stem cells alleviates COVID-19 lung injury by inhibiting pyroptosis. iScience 2022;25:104046. [PMID: 35287354 DOI: 10.1016/j.isci.2022.104046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ashraf A, Liaquat A, Shabbir S, Bokhari SA, Tariq Z, Furrukh Z, Raja AA, Khan MJ. High level of lactate dehydrogenase and ischaemia-reperfusion injury regulate the multiple organ dysfunction in patients with COVID-19. Postgrad Med J 2022:postgradmedj-2022-141573. [PMID: 35321887 DOI: 10.1136/postgradmedj-2022-141573] [Reference Citation Analysis]
19 Marcuzzi A, Rimondi E, Melloni E, Gonelli A, Grasso AG, Barbi E, Maximova N. Early Use of Low-Dose Ruxolitinib: A Promising Strategy for the Treatment of Acute and Chronic GVHD. Pharmaceuticals 2022;15:374. [DOI: 10.3390/ph15030374] [Reference Citation Analysis]
20 Yang C, Lee Y, Hsu H, Zhao G, Lee S. Tyrphostin AG1024 Suppresses Coronaviral Replication by Downregulating JAK1 via an IR/IGF-1R Independent Proteolysis Mediated by Ndfip1/2_NEDD4-like E3 Ligase Itch. Pharmaceuticals 2022;15:241. [DOI: 10.3390/ph15020241] [Reference Citation Analysis]
21 Mahboubi Mehrabani M, Karvandi MS, Maafi P, Doroudian M. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches. Rev Med Virol 2022;:e2334. [PMID: 35138001 DOI: 10.1002/rmv.2334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Chandra A, Johri A. A Peek into Pandora’s Box: COVID-19 and Neurodegeneration. Brain Sciences 2022;12:190. [DOI: 10.3390/brainsci12020190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 La Manna S, De Benedictis I, Marasco D. Proteomimetics of Natural Regulators of JAK-STAT Pathway: Novel Therapeutic Perspectives. Front Mol Biosci 2021;8:792546. [PMID: 35047557 DOI: 10.3389/fmolb.2021.792546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zununi Vahed S, Hosseiniyan Khatibi SM, Ahmadian E, Ardalan M. Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells. Biomed Pharmacother 2022;147:112614. [PMID: 34995938 DOI: 10.1016/j.biopha.2022.112614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Bektaş M, Özdemir G. Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy. Clinical Immunology 2022. [DOI: 10.1016/j.clim.2022.108936] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol 2021;:1-9. [PMID: 34860621 DOI: 10.1080/1744666X.2022.2014323] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Bande BD. Use of Tofacitinib in the Management of COVID-19 Pneumonia. Indian J Crit Care Med 2021;25:1089-90. [PMID: 34916738 DOI: 10.5005/jp-journals-10071-24004] [Reference Citation Analysis]
28 Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, Safary A. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Infection 2021. [PMID: 34902115 DOI: 10.1007/s15010-021-01730-6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
29 Bass A, Liu Y, Dakshanamurthy S. Single-Cell and Bulk RNASeq Profiling of COVID-19 Patients Reveal Immune and Inflammatory Mechanisms of Infection-Induced Organ Damage. Viruses 2021;13:2418. [PMID: 34960687 DOI: 10.3390/v13122418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Al-Karmalawy AA, Soltane R, Abo Elmaaty A, Tantawy MA, Antar SA, Yahya G, Chrouda A, Pashameah RA, Mustafa M, Abu Mraheil M, Mostafa A. Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. Vaccines (Basel) 2021;9:1317. [PMID: 34835248 DOI: 10.3390/vaccines9111317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
31 Xu L, Zhang H, Wang Y, Yang A, Dong X, Gu L, Liu D, Ding N, Jiang Y. FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE-/- mice atherosclerosis. Lab Invest 2021. [PMID: 34725437 DOI: 10.1038/s41374-021-00679-2] [Reference Citation Analysis]
32 Qi M, Liu B, Li S, Ni Z, Li F. Construction and Investigation of Competing Endogenous RNA Networks and Candidate Genes Involved in SARS-CoV-2 Infection. Int J Gen Med 2021;14:6647-59. [PMID: 34675627 DOI: 10.2147/IJGM.S335162] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Kanduc D. From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry. Antibodies (Basel) 2021;10:36. [PMID: 34698069 DOI: 10.3390/antib10040036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhang RK, Xiao Q, Zhu SL, Lin HY, Tang M. Using different machine learning models to classify patients into mild and severe cases of COVID-19 based on multivariate blood testing. J Med Virol 2022;94:357-65. [PMID: 34542195 DOI: 10.1002/jmv.27352] [Reference Citation Analysis]
35 Liao MT, Wu CC, Wu SV, Lee MC, Hu WC, Tsai KW, Yang CH, Lu CL, Chiu SK, Lu KC. Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients. Antioxidants (Basel) 2021;10:1440. [PMID: 34573071 DOI: 10.3390/antiox10091440] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
36 Buehrle DJ, Sutton RR, McCann EL, Lucas AE. A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. Viruses 2021;13:1706. [PMID: 34578287 DOI: 10.3390/v13091706] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
37 Chen CY, Chen WC, Hsu CK, Chao CM, Lai CC. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol 2021;99:108027. [PMID: 34343937 DOI: 10.1016/j.intimp.2021.108027] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
38 Pfeifer ND, Lo A, Bourdet DL, Colley K, Singh D. Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. Clin Transl Sci 2021. [PMID: 34318597 DOI: 10.1111/cts.13123] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
39 Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther 2021;6:255. [PMID: 34234112 DOI: 10.1038/s41392-021-00679-0] [Cited by in F6Publishing: 112] [Reference Citation Analysis]
40 Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. Int J Mol Sci 2021;22:6211. [PMID: 34207510 DOI: 10.3390/ijms22126211] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
41 Peter AE, Sandeep BV, Rao BG, Kalpana VL. Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-19. Front Nanotechnol 2021;3:644023. [DOI: 10.3389/fnano.2021.644023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Delshad M, Tavakolinia N, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, Bagheri N, Bashash D. The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. Int Immunopharmacol 2021;95:107586. [PMID: 33765611 DOI: 10.1016/j.intimp.2021.107586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
43 Heuberger J, Trimpert J, Vladimirova D, Goosmann C, Lin M, Schmuck R, Mollenkopf HJ, Brinkmann V, Tacke F, Osterrieder N, Sigal M. Epithelial response to IFN-γ promotes SARS-CoV-2 infection. EMBO Mol Med 2021;13:e13191. [PMID: 33544398 DOI: 10.15252/emmm.202013191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
44 Khanal P, Duyu T, Patil BM, Dey YN, Pasha I, Kavalapure RS, Chand S, Gurav S. Screening of JAK-STAT modulators from the antiviral plants of Indian traditional system of medicine with the potential to inhibit 2019 novel coronavirus using network pharmacology. 3 Biotech 2021;11:119. [PMID: 33585152 DOI: 10.1007/s13205-021-02664-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]